Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407004 | 0.80 | HCAR3 (0.38) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL27758276 | 0.80 | ALOX15 (0.41) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL2671108 | 0.78 | LMNA (0.48) | OPRK1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1407026 | 0.77 | CNR2 (0.39) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL574429 | 0.77 | TRPV4 (0.43) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL27758267 | 0.77 | ALOX15 (0.41) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL1407231 | 0.76 | POLB (0.49) | HCAR3KEAP1NFE2L2HSD11B1KDM5A | |
| SCHEMBL6052465 | 0.75 | TRPV4 (0.45) | HCAR3HSD11B1ALDH1A1KDM4E | |
| SCHEMBL1406962 | 0.75 | CNR2 (0.41) | HCAR3KEAP1NFE2L2OPRK1HSD11B1 | |
| SCHEMBL27737776 | 0.75 | HSD11B1 (0.40) | HCAR3KEAP1NFE2L2OPRK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | HCAR3 2320/4885KEAP1 599/4885NFE2L2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.